Your browser doesn't support javascript.
loading
Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort.
Reddel, Helen K; Vestbo, Jørgen; Agustí, Alvar; Anderson, Gary P; Bansal, Aruna T; Beasley, Richard; Bel, Elisabeth H; Janson, Christer; Make, Barry; Pavord, Ian D; Price, David; Rapsomaniki, Eleni; Karlsson, Niklas; Finch, Donna K; Nuevo, Javier; de Giorgio-Miller, Alex; Alacqua, Marianna; Hughes, Rod; Müllerová, Hana; Gerhardsson de Verdier, Maria.
Afiliación
  • Reddel HK; The Woolcock Institute of Medical Research and the University of Sydney, Sydney, Australia helen.reddel@sydney.edu.au.
  • Vestbo J; University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.
  • Agustí A; Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Barcelona, Spain.
  • Anderson GP; Lung Health Research Centre, Dept of Pharmacology and Therapeutics, University of Melbourne, Melbourne, Australia.
  • Bansal AT; Acclarogen, Cambridge, UK.
  • Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand.
  • Bel EH; Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Janson C; Dept of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
  • Make B; National Jewish Health and University of Colorado Denver, Denver, CO, USA.
  • Pavord ID; Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, University of Oxford, Oxford, UK.
  • Price D; Observational and Pragmatic Research Institute, Singapore.
  • Rapsomaniki E; Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
  • Karlsson N; BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Finch DK; Patient Centered Science, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
  • Nuevo J; Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • de Giorgio-Miller A; Medical Dept, BioPharmaceuticals Medical, AstraZeneca, Madrid, Spain.
  • Alacqua M; Medical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca, Luton, UK.
  • Hughes R; Respiratory and Immunology, Medical and Payer Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Müllerová H; External Scientific Engagement, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Gerhardsson de Verdier M; Respiratory and Immunology, Medical and Payer Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Eur Respir J ; 58(3)2021 09.
Article en En | MEDLINE | ID: mdl-33632799
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Médicos / Asma / Enfermedad Pulmonar Obstructiva Crónica Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Eur Respir J Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Médicos / Asma / Enfermedad Pulmonar Obstructiva Crónica Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Eur Respir J Año: 2021 Tipo del documento: Article